Measuring survival in kidney cancer trials just got a potential shortcut. A systematic review and trial-level meta-analysis published in Cancer found that disease-free survival (DFS) may serve as a valid surrogate endpoint for overall survival (OS) in patients with localized renal cell carcinoma (RCC). Since proving an OS benefit requires years of follow-up, DFS has long been used as a practical stand-in — but its reliability hadn't been firmly established until now.

The analysis, led by researchers at BC Cancer Vancouver, included 25 randomized controlled trials encompassing 16,114 patients, with a median follow-up of 61 months. Among the 13 trials included in the surrogacy analysis, treatment effects on DFS and OS showed a strong correlation.

By the Numbers:

• Weighted Pearson correlation coefficient between DFS and OS: 0.75 (95% CI, 0.55–0.91)
• DFS explained ~57% of the variability in OS treatment effects across trials
• A DFS hazard ratio below 0.914 was more likely to predict an OS benefit
• In more recent trials (2015+), correlation remained positive but less precise (r = 0.62)

Why it matters: If DFS is validated as a reliable OS surrogate, clinical trials for localized RCC adjuvant therapies could reach meaningful conclusions faster — accelerating drug approvals and getting effective treatments to patients sooner. Researchers caution, however, that these thresholds are not absolute clinical cutoffs and that individual patient-level surrogacy remains unestablished.